Jazz Pharmaceuticals (BMV:JAZZ N) - Hisse Senedi Fiyatı, Haberler ve Analizler

JAZZ N Stoklara Genel Bakış

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. Daha fazla detay

JAZZ N temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	1/6
Finansal Sağlık	1/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 77.4% daha düşük bir oranda işlem görüyor

Kazançların yılda 17.31% oranında artması öngörülüyor

Bu yıl karlı hale geldi

Risk Analizi

Hisse senetleri oldukça likit değildir

Faiz ödemeleri kazançlarla iyi karşılanmıyor

Finansal sonuçları etkileyen büyük tek seferlik kalemler

Jazz Pharmaceuticals plc Rakipler

Genomma Lab Internacional. de

BMV:LAB B

Mex$24.9b

Sichuan Kelun Pharmaceutical

SZSE:002422

CN¥48.4b

Abbott India

BSE:500488

₹588.6b

Corcept Therapeutics

NasdaqCM:CORT

US$6.0b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Jazz Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$2,027.24
52 Haftanın En Yüksek Seviyesi	US$2,027.24
52 Haftanın En Düşük Seviyesi	US$2,027.24
Beta	0.61
11 Aylık Değişim	0%
3 Aylık Değişim	n/a
1 Yıllık Değişim	n/a
33 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-32.72%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	JAZZ N	MX Pharmaceuticals	MX Pazar
7D	0%	-1.3%	-0.3%
1Y	n/a	-19.3%	-4.0%

Getiri vs. Endüstri: JAZZ N un MX Pharmaceuticals sektörüne göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Getiri vs Piyasa: JAZZ N un MX Piyasasına göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Fiyat Oynaklığı

Is JAZZ N's price volatile compared to industry and market?
JAZZ N volatility
JAZZ N Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.0%
10% most volatile stocks in MX Market	6.2%
10% least volatile stocks in MX Market	2.7%

İstikrarlı Hisse Senedi Fiyatı: JAZZ N son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: JAZZ N 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2003	2,800	Bruce Cozadd	www.jazzpharma.com

Jazz Pharmaceuticals plc Temel Bilgiler Özeti

Jazz Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
JAZZ N temel i̇stati̇sti̇kler
Piyasa değeri	Mex$114.82b
Kazançlar(TTM)	Mex$6.91b
Gelir(TTM)	Mex$63.86b

16.6x

F/K Oranı

1.8x

P/S Oranı

JAZZ N aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
JAZZ N gelir tablosu (TTM)
Gelir	US$3.83b
Gelir Maliyeti	US$284.13m
Brüt Kâr	US$3.55b
Diğer Giderler	US$3.14b
Kazançlar	US$414.83m

Son Raporlanan Kazançlar

Dec 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	6.65
Brüt Marj	92.59%
Net Kâr Marjı	10.82%
Borç/Özkaynak Oranı	153.0%

JAZZ N uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

JAZZ N Stoklara Genel Bakış

Ödüller

Risk Analizi

Jazz Pharmaceuticals plc Rakipler

BMV:LAB B

Mex$24.9b

SZSE:002422

CN¥48.4b

BSE:500488

₹588.6b

NasdaqCM:CORT

US$6.0b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-Positive (IHC 3+) Biliary Tract Cancer (BTC)

Jazz Pharmaceuticals plc Presents New Data at Psych Congress 2024 Confirming Xywav®? (Calcium, Potent, and Sodium Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

Jazz Pharmaceuticals plc to Report Q3, 2024 Results on Nov 06, 2024

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (Lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from FTSE All-World Index (USD)

Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024

Recent updates

Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-Positive (IHC 3+) Biliary Tract Cancer (BTC)

Jazz Pharmaceuticals plc Presents New Data at Psych Congress 2024 Confirming Xywav®? (Calcium, Potent, and Sodium Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

Jazz Pharmaceuticals plc to Report Q3, 2024 Results on Nov 06, 2024

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (Lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from FTSE All-World Index (USD)

Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024

gJazz Pharmaceuticals plc to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex/Epidyolex®? (Cannabidiol) At the European Epilepsy Congress 2024

Jazz Pharmaceuticals plc Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies

Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) announces an Equity Buyback for $500 million worth of its shares.

Jazz Pharmaceuticals plc Elect Laura Hamill to the Board of Directors

Jazz Pharmaceuticals plc to Report Q2, 2024 Results on Jul 25, 2024

Jazz Pharmaceuticals plc Promotes Samantha Pearce to Chief Commercial Officer

Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell 2500 Growth Index

Jazz Pharmaceuticals plc Provides Update on Phase 2b Trial of Investigational Suvecaltamide in Essential Tremor

Jazz Pharmaceuticals plc, Annual General Meeting, Jul 25, 2024

Jazz Pharmaceuticals plc Announces Catherine Sohn, Pharm.D. Will Not Stand for Re-Election to the Board

Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024

Jazz Pharmaceuticals plc Announces the U.S. Food and Drug Administration Accepted and Granted Priority Review of the Biologics License Application (BLA) for Zanidatamab

Jazz Pharmaceuticals plc Affirms Earnings Guidance for the Full Year 2024

Jazz Pharmaceuticals plc to Report Q1, 2024 Results on May 01, 2024

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024

Jazz Pharmaceuticals Announces Board Changes

Jazz Pharmaceuticals plc Appoints Philip Johnson as Executive Vice President, Effective March 1, 2024

Jazz Pharmaceuticals plc to Report Q4, 2023 Results on Feb 28, 2024

Insufficient new directors

Kim Sablich to Departure as Executive Vice President and General Manager, US of Jazz Pharmaceuticals plc on December 31, 2023

Jazz Pharmaceuticals plc to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Annual Meeting

Jazz Pharmaceuticals plc to Report Q3, 2023 Results on Nov 08, 2023

Jazz Pharmaceuticals plc Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xyw

Jazz Pharmaceuticals plc to Present Data from Trials of Bispecific Antibody Zanidatamab and Zepzelca

Jazz Pharmaceuticals plc Receives European Commission Approval for Enrylaze® for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Jazz Pharmaceuticals plc Announces Chief Financial Officer Changes, October 1, 2023

Jazz Pharmaceuticals plc Revises Earnings Guidance for the Year 2023

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Jazz Pharmaceuticals plc to Report Q2, 2023 Results on Aug 09, 2023

Jazz Pharmaceuticals plc, Annual General Meeting, Aug 03, 2023

Jazz Pharmaceuticals plc and Zymeworks Inc. Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Jazz Pharmaceuticals plc Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023

Jazz Pharmaceuticals plc Affirms Revenue Guidance for the Year 2023

Insider recently sold Mex$5.3m worth of stock

Full year 2022 earnings released: US$3.58 loss per share (vs US$5.52 loss in FY 2021)

Jazz Pharmaceuticals plc to Report Q4, 2022 Results on Mar 01, 2023

Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Phase 2 Trial Evaluating Zanidatamab in Her2-Expressing Metastatic Gastroesophageal Adenocarcinoma

Insider recently sold Mex$5.5m worth of stock

Independent Non-Executive Director recently sold Mex$1.3m worth of stock

Jazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset Epilepsies

Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes At the 2022 American Epilepsy Society Annual Meeting

Independent Director recently sold Mex$20m worth of stock

Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn)

Insider recently sold Mex$571k worth of stock

Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.86 loss in 3Q 2021)

Jazz Pharmaceuticals plc Raises Earnings Guidance for the Full Year 2022

Jazz Pharmaceuticals plc to Report Q3, 2022 Results on Nov 09, 2022

Insider recently sold Mex$189k worth of stock

Jazz Pharmaceuticals plc Reiterates Revenue Guidance for the Full Year 2022

Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex Epidyolex (Cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures

Senior VP & Chief Accounting Officer recently sold Mex$488k worth of stock